Cumberland Pharmaceuticals Sells U.S. Portfolio to Apotex for $100 Million, Shifts Focus to Drug Development

The sale signals a major strategic shift for Cumberland, which plans to focus on advancing its pipeline, including ifetroban for Duchenne muscular dystrophy (DMD). The FDA recently granted Fast Track designation for ifetroban, which has been dosed in nearly 1,400 subjects and has been "safe and well-tolerated," according to company data. Cumberland also held an end-of-Phase II meeting with the FDA to discuss DMD study results and determine the regulatory pathway forward.

Product Developments and Regulatory Updates

Amid the transition, Cumberland has continued to advance its remaining assets. Caldolor, its intravenous ibuprofen product, recently received FDA approval for an expanded indication to include post-operative pain management. The company also launched a new educational website for Sancuso, its anti-nausea patch, and ramped up national sales promotion efforts for Talicia, its Helicobacter pylori treatment, in February.

Additionally, the FDA reinstated the approval status of Vaprisol's manufacturing facility, clearing a regulatory hurdle for the hyponatremia treatment. Cumberland expects to announce further results from its ifetroban program as it transitions to a development-centric model.